➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
McKesson
McKinsey
Johnson and Johnson
Medtronic

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,557,993

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,557,993 protect, and when does it expire?

Patent 8,557,993 protects LIVALO and is included in one NDA.

Protection for LIVALO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-five patent family members in nine countries.

Summary for Patent: 8,557,993
Title:Crystalline forms of pitavastatin calcium
Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
Inventor(s): Van der Schaaf; Paul Adriaan (Hagenthal-le-Haut, FR), Blatter; Fritz (Reinach, CH), Szelagiewicz; Martin (Muenchenstein, CH), Schoening; Kai-Uwe (Oberwil, CH)
Assignee: Nissan Chemical Industries Ltd. (Tokyo, JP)
Application Number:13/664,498
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,557,993
Patent Claim Types:
see list of patent claims
Compound; Process; Composition;

Drugs Protected by US Patent 8,557,993

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-001 Aug 3, 2009 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-002 Aug 3, 2009 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-003 Aug 3, 2009 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,557,993

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03405080Feb 12, 2003

International Family Members for US Patent 8,557,993

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004212160   Start Trial
Canada 2513837   Start Trial
Canada 2785954   Start Trial
China 100374422   Start Trial
China 101219992   Start Trial
China 102285916   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Harvard Business School
Merck
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.